Neurotoxin-based models of Parkinson's disease

Neuroscience

Volumn 211, Issue , 2012, Pages 51-76

  Bove J ^a   Perier, C ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

6 hydroxydopamine; Animal models; MPTP; Paraquat; Parkinson's disease; Rotenone

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; CASPASE 3; CASPASE 9; DOPAMINE; DOPAMINE TRANSPORTER; LEVODOPA; NEUROTOXIN; OXIDOPAMINE; PARAQUAT; PROTEIN BAX; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE;

APOPTOSIS; BASAL GANGLION; BEHAVIOR CHANGE; BRAIN DEPTH STIMULATION; BRAIN MITOCHONDRION; DISEASE MODEL; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DYSKINESIA; HUMAN; LEWY BODY; MEDIAL FOREBRAIN BUNDLE; MICROGLIA; MOTOR DYSFUNCTION; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SUBTHALAMIC NUCLEUS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BEHAVIOR, ANIMAL; CELL DEATH; DISEASE MODELS, ANIMAL; NEUROTOXINS; OXIDOPAMINE; PARAQUAT; PARKINSON DISEASE, SECONDARY; ROTENONE;

EID: 84860615324     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.10.057     Document Type: Review

References (351)

1. Agid Y., Javoy-Agid F., Ruberg M. Biochemistry of neurotransmitters in Parkinson's disease. Movement disorders 2 1987, 166-230. Butterworths, London. C.D. Marsden, S. Fahn (Eds.).
2. Aguiar L.M., Nobre H.V., Macêdo D.S., Oliveira A.A., Freitas R.M., Vasconcelos S.M., Cunha G.M., Sousa F.C., Viana G.S. Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats. Pharmacol Biochem Behav 2006, 84:415-419.
3. Alam M., Danysz W., Schmidt W.J., Dekundy A. Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats. Toxicol Appl Pharmacol 2009, 240:198-207.
4. Alam M., Schmidt W.J. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res 2002, 136:317-324.
5. Alam M., Schmidt W.J. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats. Behav Brain Res 2004, 153:439-446.
6. Alam Z.I., Daniel S.E., Lees A.J., Marsden D.C., Jenner P., Halliwell B. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy Body disease. J Neurochem 1997, 69:1326-1329.
7. Alam Z.I., Jenner A., Daniel S.E., Lees A.J., Cairns N., Marsden C.D., Jenner P., Halliwell B. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 1997, 69:1196-1203.
8. Alvarez-Fischer D., Guerreiro S., Hunot S., Saurini F., Marien M., Sokoloff P., Hirsch E.C., Hartmann A., Michel P.P. Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid. J Neurochem 2008, 107:701-711.
9. Alvarez-Fischer D., Henze C., Strenzke C., Westrich J., Ferger B., Hoglinger G.U., Oertel W.H., Hartmann A. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Exp Neurol 2008, 210:182-193.
10. Ambani L.M., Van Woert M.H., Murphy S. Brain peroxidase and catalase in Parkinson disease. Arch Neurol 1975, 32:114-118.
11. Andreassen O.A., Ferrante R.J., Dedeoglu A., Albers D.W., Klivenyi P., Carlson E.J., Epstein C.J., Beal M.F. Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3 nitropropionic acid, and MPTP. Exp Neurol 2001, 167:189-195.
12. Andrew R., Watson D.G., Best S.A., Midgley J.M., Wenlong H., Petty R.K. The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem Res 1993, 18:1175-1177.
13. Arthur C.R., Morton S.L., Dunham L.D., Keeney P.M., Bennett J.P. Parkinson's disease brain mitochondria have impaired respirasome assembly, age-related increases in distribution of oxidative damage to mtDNA and no differences in heteroplasmic mtDNA mutation abundance. Mol Neurodegener 2009, 4:37.
14. Asanuma M., Hirata H., Cadet J.L. Attenuation of 6-hydroxydopamine-induced dopaminergic nigrostriatal lesions in superoxide dismutase transgenic mice. Neuroscience 1998, 85:907-917.
15. Ascherio A., Zhang S.M., Hernán M.A., Kawachi I., Colditz G.A., Speizer F.E., Willett W.C. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001, 50:56-63.
16. Aubin N., Curet O., Deffois A., Carter C. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 1998, 71:1635-1642.
17. Bankiewicz K.S., Oldfield E.H., Chiueh C.C., Doppman J.L., Jacobowitz D.M., Kopin I.J. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci 1986, 39:7-16.
18. Bara-Jimenez W., Dimitrova T., Sherzai A., Favit A., Mouradian M.M., Chase T.N. Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease. Mov Disord 2004, 19:1183-1186.
19. Barraud Q., Lambrecq V., Forni C., McGuire S., Hill M., Bioulac B., Balzamo E., Bezard E., Tison F., Ghorayeb I. Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model. Exp Neurol 2009, 219:574-582.
20. Bensadoun J.C., Mirochnitchenko O., Inouye M., Aebischer P., Zurn A.D. Attenuation of 6-OHDA-induced neurotoxicity in glutathione peroxidase transgenic mice. Eur J Neurosci 1998, 10:3231-3236.
21. Ben-Shachar D., Eshel G., Finberg J.P., Youdim M.B. The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 1991, 56:1441-1444.
22. Bergman H., Wichmann T., DeLong M.R. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990, 249:1436-1438.
23. Berry C., La Vecchia C., Nicotera P. Paraquat and Parkinson's disease. Cell Death Differ 2010, 17:1115-1125.
24. Betarbet R., Canet-Aviles R.M., Sherer T.B., Mastroberardino P.G., McLendon C., Kim J.H., Lund S., Na H.M., Taylor G., Bence N.F., Kopito R., Seo B.B., Yagi T., Yagi A., Klinefelter G., Cookson M.R., Greenamyre J.T. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis 2006, 22:404-420.
25. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000, 3:1301-1306.
26. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Crossman A.R., Bioulac B., Brotchie J.M., Gross C.E. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 2001, 21:6853-6861.
27. Bezard E., Gross C.E., Fournier M.C., Dovero S., Bloch B., Jaber M. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp Neurol 1999, 155:268-273.
28. Bezard E., Imbert C., Deloire X., Bioulac B., Gross C.E. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Res 1997, 766:107-112.
29. Bezard E., Ravenscroft P., Gross C.E., Crossman A.R., Brotchie J.M. Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys. Neurobiol Dis 2001, 8:343-350.
30. Bjorklund L.M., Sánchez-Pernaute R., Chung S., Andersson T., Chen I.Y., McNaught K.S., Brownell A.L., Jenkins B.G., Wahlestedt C., Kim K.S., Isacson O. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci U S A 2002, 99:2344-2349.
31. Blanchet P.J., Calon F., Morissette M., Hadj T.A., Bélanger N., Samadi P., Grondin R., Grégoire L., Meltzer L., Di Paolo T., Bédard P.J. Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. Parkinsonism Relat Disord 2004, 10:297-304.
32. Blandini F., Armentero M.T., Martignoni E. The 6-hydroxydopamine model: news from the past. Parkinsonism Relat Disord 2008, 14(Suppl 2):S124-S129.
33. Blandini F., Cova L., Armentero M.T., Zennaro E., Levandis G., Bossolasco P., Calzarossa C., Mellone M., Giuseppe B., Deliliers G.L., Polli E., Nappi G., Silani V. Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat. Cell Transplant 2010, 19:203-217.
34. Blume S.R., Cass D.K., Tseng K.Y. Stepping test in mice: a reliable approach in determining forelimb akinesia in MPTP-induced Parkinsonism. Exp Neurol 2009, 219:208-211.
35. Borisenko G.G., Kagan V.E., Hsia C.J., Schor N.F. Interaction between 6-hydroxydopamine and transferrin: "let my iron go". Biochemistry 2000, 39:3392-3400.
36. Bourn W.M., Chin L., Picchioni A.L. Enhancement of audiogenic seizure by 6-hydroxydopamine. J Pharm Pharmacol 1972, 24:913-914.
37. Bové J., Marin C., Bonastre M., Tolosa E. Adenosine A2A antagonism reverses L-dopa-induced motor alterations in hemiparkinsonian rats. Synapse 2002, 46:251-257.
38. Bove J., Prou D., Perier C., Przedborski S. Toxin-induced models of Parkinson's disease. Neurorx 2005, 2:484-494.
39. Bove J., Serrats J., Mengod G., Cortes R., Aguilar E., Marin C. Reversion of L-dopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats. Synapse 2006, 59:435-444.
40. Bove J., Serrats J., Mengod G., Cortes R., Tolosa E., Marin C. Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways. Exp Brain Res 2005, 165:362-374.
41. Bove J., Zhou C., Jackson-Lewis V., Taylor J., Chu Y., Rideout H.J., Wu D.C., Kordower J.H., Petrucelli L., Przedborski S. Proteasome inhibition and Parkinson's disease modeling. Ann Neurol 2006, 60:260-264.
42. Boyce S., Kelly E., Reavill C., Jenner P., Marsden C.D. Repeated administration of N-methyl-4-phenyl 1,2,5,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones. Biochem Pharmacol 1984, 33:1747-1752.
43. Braak H., Del Tredici K., Bratzke H., Hamm-Clement J., Sandmann-Keil D., Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002, 249(Suppl 3):III/1-III/5.
44. Brinkley B.R., Barham S.S., Barranco S.C., Fuller G.M. Rotenone inhibition of spindle microtubule assembly in mammalian cells. Exp Cell Res 1974, 85:41-46.
45. + lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009, 119:182-192.
46. Brooks A.I., Chadwick C.A., Gelbard H.A., Cory-Slechta D.A., Federoff H.J. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res 1999, 823:1-10.
47. Broom L., Marinova-Mutafchieva L., Sadeghian M., Davis J.B., Medhurst A.D., Dexter D.T. Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease. Free Radic Biol Med 2011, 50:633-640.
48. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of substantia nigra by N-methyl-4-phenyl,1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A 1983, 80:4546-4550.
49. Cadet J.L., Katz M., Jackson-Lewis V., Fahn S. Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res 1989, 476:10-15.
50. Caneda-Ferrón B., De Girolamo L.A., Costa T., Beck K.E., Layfield R., Billett E.E. Assessment of the direct and indirect effects of MPP+ and dopamine on the human proteasome: implications for Parkinson's disease aetiology. J Neurochem 2008, 105:225-238.
51. Cannon J.R., Tapias V., Na H.M., Honick A.S., Drolet R.E., Greenamyre J.T. A highly reproducible rotenone model of Parkinson's disease. Neurobiol Dis 2009, 34:279-290.
52. Carlsson A., Lindqvist M., Magnusson T., Waldeck B. On the presence of 3-hydroxytyramine in brain. Science 1958, 127:471.
53. Carlsson A., Lindqvist M., Magnusson T. 3,4-dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957, 180:1200.
54. Cenci M.A., Lee C.S., Björklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998, 10:2694-2706.
55. Cenci M.A., Ohlin K.E. Rodent models of treatment-induced motor complications in Parkinson's disease. Parkinsonism Relat Disord 2009, 15(Suppl 4):S13-S17.
56. Chan P., DeLanney L.E., Irwin I., Langston J.W., Di Monte D. Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J Neurochem 1991, 57:348-351.
57. Chang J.W., Wachtel S.R., Young D., Kang U.J. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 1999, 88:617-628.
58. Chaudhuri K.R., Healy D.G., Schapira A.H. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006, 5:235-245.
59. Chen H., Huang X., Guo X., Mailman R.B., Park Y., Kamel F., Umbach D.M., Xu Q., Hollenbeck A., Schatzkin A., Blair A. Smoking duration, intensity, and risk of Parkinson disease. Neurology 2010, 74:878-884.
60. Chen J.F., Xu K., Petzer J.P., Staal R., Xu Y.H., Beilstein M., Sonsalla P.K., Castagnoli K., Castagnoli N., Schwarzschild M.A. Neuroprotection by caffeine and A (2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001, 21:RC143.
61. Cheng H.C., Kim S.R., Oo T.F., Kareva T., Yarygina O., Rzhetskaya M., Wang C., During M., Talloczy Z., Tanaka K., Komatsu M., Kobayashi K., Okano H., Kholodilov N., Burke R.E. Akt suppresses retrograde degeneration of dopaminergic axons by inhibition of macroautophagy. J Neurosci 2011, 31:2125-2135.
62. Chiba K., Kubota E., Miyakawa T., Kato Y., Ishizaki T. Characterization of hepatic microsomal metabolism as an in vivo detoxication pathway of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Pharmacol Exp Ther 1988, 246:1108-1115.
63. Chiba K., Peterson L.A., Castagnoli K.P., Trevor A.J., Castagnoli N. Studies on the molecular mechanism of bioactivation of the selective nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Drug Metab Dispos 1985, 13:342-347.
64. Chiba K., Trevor A., Castagnoli N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984, 120:574-578.
65. Chiueh C.C., Markey S.P., Burns R.S., Johannessen J.N., Pert A., Kopin I.J. Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. Eur J Pharmacol 1984, 100:189-194.
66. Choi W.S., Palmiter R.D., Xia Z. Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson's disease model. J Cell Biol 2011, 192:873-882.
67. Chou A.P., Li S., Fitzmaurice A.G., Bronstein J.M. Mechanisms of rotenone-induced proteasome inhibition. Neurotoxicology 2010, 31:367-372.
68. Cicchetti F., Brownell A.L., Williams K., Chen Y.I., Livni E., Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 2002, 15:991-998.
69. Close S.P., Elliott P.J., Hayes A.G., Marriott A.S. Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease. Psychopharmacology (Berl) 1990, 102:295-300.
70. Cohen G. Oxy-radical toxicity in catecholamine neurons. Neurotoxicology 1984, 5:77-82.
71. Cohen G., Heikkila R.E. The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J Biol Chem 1974, 249:2447-2452.
72. Collier T.J., Kanaan N.M., Kordower J.H. Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat Rev Neurosci 2011, 12:359-366.
73. Collier T.J., Lipton J., Daley B.F., Palfi S., Chu Y., Sortwell C., Bakay R.A., Sladek J.R., Kordower J.H. Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to Parkinsonism. Neurobiol Dis 2007, 26:56-65.
74. Cory-Slechta D.A., Thiruchelvam M., Di Monte D.A. Letter regarding: "Paraquat: the red herring of Parkinson's disease research.". Toxicol Sci 2008, 103:215-216.
75. Costa J., Lunet N., Santos C., Santos J., Vaz-Carneiro A. Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studies. J Alzheimers Dis 2010, 20(Suppl 1):S221-S238.
76. Cotzias G.C., Papavasiliou P.S., Gellene R. Experimental treatment of parkinsonism with L-dopa. Neurology 1968, 18:276-277.
77. Crocker C.E., Khan S., Cameron M.D., Robertson H.A., Robertson G.S., LoGrasso P. JNK inhibition protects dopamine neurons and provides behavioral improvement in a Rat 6-hydroxydopamine model of Parkinson's disease. ACS Chem Neurosci 2011, 2:207-212.
78. Crocker S.J., Lamba W.R., Smith P.D., Callaghan S.M., Slack R.S., Anisman H., Park D.S. C-Jun mediates axotomy-induced dopamine neuron death in vivo. Proc Natl Acad Sci U S A 2001, 98:13385-13390.
79. Crocker S.J., Wigle N., Liston P., Thompson C.S., Lee C.J., Xu D., Roy S., Nicholson D.W., Park D.S., MacKenzie A., Korneluk R.G., Robertson G.S. NAIP protects the nigrostriatal dopamine pathway in an intrastriatal 6-OHDA rat model of Parkinson's disease. Eur J Neurosci 2001, 14:391-400.
80. Curtius H.C., Wolfensberger M., Steinmann B., Redweik U., Siegfried J. Mass fragmentography of dopamine and 6-hydroxydopamine. Application to the determination of dopamine in human brain biopsies from the caudate nucleus. J Chromatogr 1974, 99:529-540.
81. Cutillas B., Espejo M., Gil J., Ferrer I., Ambrosio S. Caspase inhibition protects nigral neurons against 6-OHDA-induced retrograde degeneration. Neuroreport 1999, 10:2605-2608.
82. Członkowska A., Kohutnicka M., Kurkowska-Jastrzebska I., Członkowski A. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 1996, 5:137-143.
83. Dauer W., Kholodilov N., Vila M., Trillat A.C., Goodchild R., Larsen K.E., Staal R., Tieu K., Schmitz Y., Yuan C.A., Rocha M., Jackson-Lewis V., Hersch S., Sulzer D., Przedborski S., Burke R., Hen R. Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A 2002, 99:14524-14529.
84. Davey G.P., Tipton K.F., Murphy M.P. Uptake and accumulation of 1-methyl-4-phenylpyridinium by rat liver mitochondria measured using an ion-selective electrode. Biochem J 1992, 288:439-443.
85. Davis G.C., Williams A.C., Markey S.P., Ebert M.H., Caine E.D., Reichert C.M., Kopin I.J. Chronic parkinsonism secondary to intravenous injection of meperidine analogs. Psychiatry Res 1979, 1:249-254.
86. Day B.J., Patel M., Calavetta L., Chang L.Y., Stamler J.S. A mechanism of paraquat toxicity involving nitric oxide synthase. Proc Natl Acad Sci U S A 1999, 96:12760-12765.
87. de Rijk M.C., Tzourio C., Breteler M.M., Dartigues J.F., Amaducci L., Lopez-Pousa S., Manubens-Bertran J.M., Alperovitch A., Rocca W.A. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON collaborative study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997, 62:10-15.
88. Decamp E., Schneider J.S. Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates. Eur J Neurosci 2004, 20:1371-1378.
89. Decamp E., Schneider J.S. Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model. Brain Res 2009, 1262:109-114.
90. Dehay B., Bové J., Rodríguez-Muela N., Perier C., Recasens A., Boya P., Vila M. Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci 2010, 30:12535-12544.
91. Dehmer T., Lindenau J., Haid S., Dichgans J., Schulz J.B. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem 2000, 74:2213-2216.
92. Depino A.M., Earl C., Kaczmarczyk E., Ferrari C., Besedovsky H., del Rey A., Pitossi F.J., Oertel W.H. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci 2003, 18:2731-2742.
93. Deumens R., Blokland A., Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 2002, 175:303-317.
94. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Agid Y., Lees A., Jenner P., Marsden C.D. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989, 52:381-389.
95. Dhillon A.S., Tarbutton G.L., Levin J.L., Plotkin G.M., Lowry L.K., Nalbone J.T., Shepherd S. Pesticide/environmental exposures and Parkinson's disease in East Texas. J Agromedicine 2008, 13:37-48.
96. Dowd E., Monville C., Torres E.M., Dunnett S.B. The corridor task: a simple test of lateralised response selection sensitive to unilateral dopamine deafferentation and graft-derived dopamine replacement in the striatum. Brain Res Bull 2005, 68:24-30.
97. Drolet R.E., Cannon J.R., Montero L., Greenamyre J.T. Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiol Dis 2009, 36:96-102.
98. Ebersbach G., Stöck M., Müller J., Wenning G., Wissel J., Poewe W. Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration. Mov Disord 1999, 14:1011-1013.
99. Ebert A.D., Hann H.J., Bohn M.C. Progressive degeneration of dopamine neurons in 6-hydroxydopamine rat model of Parkinson's disease does not involve activation of caspase-9 and caspase-3. J Neurosci Res 2008, 86:317-325.
100. Ehringer H., Hornykiewicz O. Verteilung von Noradrenalin und dopamine (3-hydroxytyramin) im gehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidalen systems. Wiener Klinische Wochenschrift 1960, 38:1236-1239.
101. Emborg M.E., Moirano J., Raschke J., Bondarenko V., Zufferey R., Peng S., Ebert A.D., Joers V., Roitberg B., Holden J.E., Koprich J., Lipton J., Kordower J.H., Aebischer P. Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiol Dis 2009, 36:303-311.
102. Eriksen N., Stark A.K., Pakkenberg B. Age and Parkinson's disease-related neuronal death in the substantia nigra pars compacta. J Neural Transm Suppl 2009, 73:203-213.
103. Facheris M.F., Schneider N.K., Lesnick T.G., de Andrade M., Cunningham J.M., Rocca W.A., Maraganore D.M. Coffee, caffeine-related genes, and Parkinson's disease: a case-control study. Mov Disord 2008, 23:2033-2040.
104. Fahn S. The case of the frozen addicts: how the solution of an extraordinary medical mystery spawned a revolution in the understanding and treatment of Parkinson's disease. N Engl J Med 1996, 335(26):2002-2003.
105. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 2003, 991:1-14.
106. Faull R.L., Laverty R. Changes in dopamine levels in the corpus striatum following lesions in the substantia nigra. Exp Neurol 1969, 23:332-340.
107. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114(Pt 5):2283-2301.
108. Fei Q., McCormack A.L., Di Monte D.A., Ethell D.W. Paraquat neurotoxicity is mediated by a bak-dependent mechanism. J Biol Chem 2008, 283:3357-3364.
109. Ferger B., Teismann P., Earl C.D., Kuschinsky K., Oertel W.H. The protective effects of PBN against MPTP toxicity are independent of hydroxyl radical trapping. Pharmacol Biochem Behav 2000, 65:425-431.
110. Fernagut P.O., Hutson C.B., Fleming S.M., Tetreaut N.A., Salcedo J., Masliah E., Chesselet M.F. Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse 2007, 61:991-1001.
111. Ferrante R.J., Schulz J.B., Kowall N.W., Beal M.F. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res 1997, 753:157-162.
112. Fleming S.M., Zhu C., Fernagut P.O., Mehta A., Dicarlo C.D., Seaman R.L., Chesselet M.F. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp Neurol 2004, 187:418-429.
113. Fornai F., Schlüter O.M., Lenzi P., Gesi M., Ruffoli R., Ferrucci M., Lazzeri G., Busceti C.L., Pontarelli F., Battaglia G., Pellegrini A., Nicoletti F., Ruggieri S., Paparelli A., Südhof T.C. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci U S A 2005, 102:3413-3418.
114. Forno L.S., DeLanney L.E., Irwin I., Langston J.W. Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease: neuropathologic considerations. Adv Neurol 1993, 60:600-608.
115. Fox S.H., Brotchie J.M. The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future. Prog Brain Res 2010, 184:133-157.
116. Fox S.H., Visanji N., Reyes G., Huot P., Gomez-Ramirez J., Johnston T., Brotchie J.M. Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease. Can J Neurol Sci 2010, 37:86-95.
117. Garrido-Gil P., Belzunegui S., San Sebastián W., Izal-Azcárate A., López B., Marcilla I., Luquin M.R. 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine exposure fails to produce delayed degeneration of substantia nigra neurons in monkeys. J Neurosci Res 2009, 87:586-597.
118. Gerfen C.R., Baimbridge K.G., Miller J.J. The neostriatal mosaic: compartmental distribution of calcium-binding protein and parvalbumin in the basal ganglia of the rat and monkey. Proc Natl Acad Sci U S A 1985, 82:8780-8784.
119. Gerfen C.R., Baimbridge K.G., Thibault J. The neostriatal mosaic: part III. Biochemical and developmental dissociation of patch-matrix nigrostriatal system. J Neurosci 1987, 7:3935-3944.
120. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J., Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990, 250:1429-1432.
121. Gerfen C.R., Herkenham M., Thibault J. The neostriatal mosaic: part II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems. J Neurosci 1987, 7:3915-3934.
122. Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., Eggert K., Oertel W., Banati R.B., Brooks D.J. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 2006, 21:404-412.
123. German D.C., Manaye K.F., Sonsalla P.K., Brooks B.A. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced Parkinsonism: sparing of calbindin-D28k-containing cells. Ann N Y Acad Sci 1992, 648:42-62.
124. Ghosh B., Antonio T., Reith M.E., Dutta A.K. Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson's disease. J Med Chem 2010, 53:2114-2125.
125. Giovanni A., Sonsalla P.K., Heikkila R.E. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. part 2: central administration of 1-methyl-4-phenylpyridinium. J Pharmacol Exp Ther 1994, 270:1008-1014.
126. Goetz C.G., Tilley B.C., Shaftman S.R., Stebbins G.T., Fahn S., Martinez-Martin P., Poewe W., Sampaio C., Stern M.B., Dodel R., Dubois B., Holloway R., Jankovic J., Kulisevsky J., Lang A.E., Lees A., Leurgans S., LeWitt P.A., Nyenhuis D., Olanow C.W., Rascol O., Schrag A., Teresi J.A., Van Hilten J.J., LaPelle N. Movement Disorder Society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008, 23:2129-2170.
127. Grant H., Lantos P.L., Parkinson C. Cerebral damage in paraquat poisoning. Histopathology 1980, 4:185-195.
128. Grealish S., Mattsson B., Draxler P., Björklund A. Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease. Eur J Neurosci 2010, 31:2266-2278.
129. Gründemann J., Schlaudraff F., Haeckel O., Liss B. Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease. Nucleic Acids Res 2008, 36:e38.
130. Hadaczek P., Eberling J.L., Pivirotto P., Bringas J., Forsayeth J., Bankiewicz K.S. Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther 2010, 18:1458-1461.
131. Halliday G., Herrero M.T., Murphy K., McCann H., Ros-Bernal F., Barcia C., Mori H., Blesa F.J., Obeso J.A. No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism. Mov Disord 2009, 24:1519-1523.
132. Hanrott K., Murray T.K., Orfali Z., Ward M., Finlay C., O'Neill M.J., Wonnacott S. Differential activation of PKC delta in the substantia nigra of rats following striatal or nigral 6-hydroxydopamine lesions. Eur J Neurosci 2008, 27:1086-1096.
133. Hansard M.J., Smith L.A., Jackson M.J., Cheetham S.C., Jenner P. Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J Pharmacol Exp Ther 2002, 303:952-958.
134. Hantraye P., Varastet M., Peschanski M., Riche D., Cesaro P., Willer J.C., Maziere M. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons. Neuroscience 1993, 53:169-178.
135. Harms A.S., Barnum C.J., Ruhn K.A., Varghese S., Treviño I., Blesch A., Tansey M.G. Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease. Mol Ther 2011, 19:46-52.
136. Hartmann A., Hunot S., Michel P.P., Muriel M.P., Vyas S., Faucheux B.A., Mouatt-Prigent A., Turmel H., Srinivasan A., Ruberg M., Evan G.I., Agid Y., Hirsch E.C. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A 2000, 97:2875-2880.
137. Hasegawa E., Takeshige K., Oishi T., Murai Y., Minakami S. 1-Mehtyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem Biophys Res Commun 1990, 170:1049-1055.
138. Hassani O.K., Mouroux M., Féger J. Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus. Neuroscience 1996, 72:105-115.
139. Hauser R.A., Salin L., Juhel N., Konyago V.L. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. Mov Disord 2007, 22:359-365.
140. Hefti F., Melamed E., Wurtman R.J. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Res 1980, 195:123-137.
141. Heikkila R., Cohen G. Further studies on the generation of hydrogen peroxide by 6-hydroxydopamine. Potentiation by ascorbic acid. Mol Pharmacol 1972, 8:241-248.
142. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science 1984, 224:1451-1453.
143. Heikkila R.E., Nicklas W.J., Vays I., Duvoisin R.C. Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Neurosci Lett 1985, 62:389-394.
144. Hisata J. Lake and stream rehabilitation: rotenone use and health risks 2002, Department of Fish and Wildlife, Washington, Final supplemental environmental impact statement.
145. Hoglinger G.U., Feger J., Annick P., Michel P.P., Karine P., Champy P., Ruberg M., Wolfgang W.O., Hirsch E. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem 2003, 84:1-12.
146. Hoglinger G.U., Lannuzel A., Khondiker M.E., Michel P.P., Duyckaerts C., Féger J., Champy P., Prigent A., Medja F., Lombes A., Oertel W.H., Ruberg M., Hirsch E.C. The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem 2005, 95:930-939.
147. Hoglinger G.U., Oertel W.H., Hirsch E.C. The rotenone model of Parkinsonism-the five years inspection. J Neural Transm Suppl 2006, 70:269-272.
148. Hoglinger G.U., Rizk P., Muriel M.P., Duyckaerts C., Oertel W.H., Caille I., Hirsch E.C. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 2004, 7:726-735.
149. Hoppel C.L., Grinblatt D., Kwok H.C., Arora P.K., Singh M.P., Sayre L.M., Greenblatt D. Inhibition of mitochondrial respiration by analogs of 4-phenylpyridine and 1-methyl-4-phenylpyridinium cation (MPP+), the neurotoxic metabolite of MPTP. Biochem Biophys Res Commun 1987, 148:684-693.
150. Hu L.F., Lu M., Tiong C.X., Dawe G.S., Hu G., Bian J.S. Neuroprotective effects of hydrogen sulfide on Parkinson's disease rat models. Aging Cell 2010, 9:135-146.
151. Hu X., Weng Z., Chu C.T., Zhang L., Cao G., Gao Y., Signore A., Zhu J., Hastings T., Greenamyre J.T., Chen J. Peroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade. J Neurosci 2011, 31:247-261.
152. Huang L.Z., Parameswaran N., Bordia T., Michael M.J., Quik M. Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys. J Neurochem 2009, 109:826-837.
153. Hughes J.T. Brain damage due to paraquat poisoning: a fatal case with neuropathological examination of the brain. Neurotoxicology 1988, 9:243-248.
154. Hunot S., Vila M., Teismann P., Davis R.J., Hirsch E.C., Przedborski S., Rakic P., Flavell R.A. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 2004, 101:665-670.
155. Hutter-Saunders JA, Gendelman HE, Mosley RL (in press) Murine motor and behavior functional evaluations for acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication. J Neuroimmune Pharmacol, in press.
156. Iancu R., Mohapel P., Brundin P., Paul G. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res 2005, 162:1-10.
157. Ikeda K., Kurokawa M., Aoyama S., Kuwana Y. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J Neurochem 2002, 80:262-270.
158. Imbert C., Bezard E., Guitraud S., Boraud T., Gross C.E. Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the macaque monkey. J Neurosci Methods 2000, 96:71-76.
159. Inden M., Kitamura Y., Abe M., Tamaki A., Takata K., Taniguchi T. Parkinsonian rotenone mouse model: reevaluation of long-term administration of rotenone in C57BL/6 mice. Biol Pharm Bull 2011, 34:92-96.
160. Inden M., Kitamura Y., Takeuchi H., Yanagida T., Takata K., Kobayashi Y., Taniguchi T., Yoshimoto K., Kaneko M., Okuma Y., Taira T., Ariga H., Shimohama S. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J Neurochem 2007, 101:1491-1504.
161. Inden M., Kitamura Y., Tamaki A., Yanagida T., Shibaike T., Yamamoto A., Takata K., Yasui H., Taira T., Ariga H., Taniguchi T. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice. Neurochem Int 2009, 55:760-767.
162. Iravani M.M., Syed E., Jackson M.J., Johnston L.C., Smith L.A., Jenner P. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets. Eur J Neurosci 2005, 21:841-854.
163. Itti E., Villafane G., Malek Z., Brugières P., Capacchione D., Itti L., Maison P., Cesaro P., Meignan M. Dopamine transporter imaging under high-dose transdervmal nicotine therapy in Parkinson's disease: an observational study. Nucl Med Commun 2009, 30:513-518.
164. Jackson M.J., Andree T.H., Hansard M., Hoffman D.C., Hurtt M.R., Kehne J.H., Pitler T.A., Smith L.A., Stack G., Jenner P. The dopamine D (2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa. J Neural Transm 2010, 117:55-67.
165. Jackson-Lewis V., Jakowec M., Burke R.E., Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 1995, 4:257-269.
166. Jackson-Lewis V., Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2007, 2:141-151.
167. Jakowec M.W., Petzinger G.M. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of Parkinson's disease, with emphasis on mice and nonhuman primates. Comp Med 2004, 54:497-513.
168. Janson A.M., Fuxe K., Sundström E., Agnati L.F., Goldstein M. Chronic nicotine treatment partly protects against the 1-methyl-4-phenyl-2,3,6-tetrahydropyridine-induced degeneration of nigrostriatal dopamine neurons in the black mouse. Acta Physiol Scand 1988, 132:589-591.
169. Javitch J.A., D'Amato R.J., Strittmatter S.M., Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridinium by dopamine neurons explain selective toxicity. Proc Natl Acad Sci U S A 1985, 82:2173-2177.
170. Jenner P. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. Parkinsonism Relat Disord 2003, 9:131-137.
171. Jenner P. The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications. Neurology 2003, 61:S4-S11.
172. Jenner P., Rose S., Nomoto M., Marsden C.D. MPTP-induced parkinsonism in the common marmoset: behavioral and biochemical effects. Adv Neurol 1987, 45:183-186.
173. Jenner P., Rupniak N.M., Rose S., Kelly E., Kilpatrick G., Lees A., Marsden C.D. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci Lett 1984, 50:85-90.
174. Jeon B.S., Jackson-Lewis V., Burke R.E. 6-hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. Neurodegeneration 1995, 4:131-137.
175. Jeon B.S., Kholodilov N.G., Oo T.F., Kim S.Y., Tomaselli K.J., Srinivasan A., Stefanis L., Burke R.E. Activation of caspase-3 in developmental models of programmed cell death in neurons of the substantia nigra. J Neurochem 1999, 73:322-333.
176. Joghataie M.T., Roghani M., Negahdar F., Hashemi L. Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence. Parkinsonism Relat Disord 2004, 10:465-468.
177. Johnston L.C., Jackson M.J., Rose S., McCreary A.C., Jenner P. Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets. Mov Disord 2010, 25:2059-2066.
178. Johnston T.H., Huot P., Fox S.H., Wakefield J.D., Sykes K.A., Bartolini W.P., Milne G.T., Pearson J.P., Brotchie J.M. Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease. J Pharmacol Exp Ther 2011, 336:423-430.
179. Jungnickel J., Kalve I., Reimers L., Nobre A., Wesemann M., Ratzka A., Halfer N., Lindemann C., Schwabe K., Töllner K., Gernert M., Grothe C. Topology of intrastriatal dopaminergic grafts determines functional and emotional outcome in neurotoxin-lesioned rats. Behav Brain Res 2011, 216:129-135.
180. Kachroo A., Irizarry M.C., Schwarzschild M.A. Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Exp Neurol 2010, 223:657-661.
181. Karachi C., Grabli D., Bernard F.A., Tandé D., Wattiez N., Belaid H., Bardinet E., Prigent A., Nothacker H.P., Hunot S., Hartmann A., Lehéricy S., Hirsch E.C., François C. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J Clin Invest 2010, 120:2745-2754.
182. Karunakaran S., Diwakar L., Saeed U., Agarwal V., Ramakrishnan S., Iyengar S., Ravindranath V. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid. FASEB J 2007, 21:2226-2236.
183. *nAChRs. J Neurochem 2007, 100:180-190.
184. Kirik D., Georgievska B., Burger C., Winkler C., Muzyczka N., Mandel R.J., Bjorklund A. Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc Natl Acad Sci U S A 2002, 99:4708-4713.
185. Kirik D., Rosenblad C., Björklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 1998, 152:259-277.
186. Kish S.J., Morito C.L., Hornykiewicz O. Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett 1985, 58:343-346.
187. Kitamura Y., Kakimura J., Taniguchi T. Protective effect of talipexole on MPTP-treated planarian, a unique parkinsonian worm model. Jpn J Pharmacol 1998, 78:23-29.
188. Klivenyi P., St.Clair D., Wermer M., Yen H.C., Oberley T., Yang L., Beal M.F. Manganese superoxide dismutase overexpression attenuates MPTP toxicity. Neurobiol Dis 1998, 5:253-258.
189. Kohutnicka M., Lewandowska E., Kurkowska-Jastrzebska I., Czlonkowski A., Czlonkowska A. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Immunopharmacol 1998, 39:167-180.
190. Kopin I.J. MPTP: an industrial chemical and contaminant of illicit narcotics stimulates a new era in research on Parkinson's disease. Environ Health Perspect 1987, 75:45-51.
191. Koprich J.B., Fox S.H., Johnston T.H., Goodman A., Le Bourdonnec B., Dolle R.E., Dehaven R.N., Dehaven-Hudkins D.L., Little P.J., Brotchie J.M. The selective mu-opioid receptor antagonist adl5510 reduces L-dopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease. Mov Disord 2011, 26:1225-1233.
192. Kostic V., Przedborski S., Flaster E., Sternic N. Early development of L-dopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991, 41:202-205.
193. Krackow S., Vannoni E., Codita A., Mohammed A.H., Cirulli F., Branchi I., Alleva E., Reichelt A., Willuweit A., Voikar V., Colacicco G., Wolfer D.P., Buschmann J.U., Safi K., Lipp H.P. Consistent behavioral phenotype differences between inbred mouse strains in the IntelliCage. Genes Brain Behav 2010, 9:722-731.
194. Kurkowska-Jastrzebska I., Wrońska A., Kohutnicka M., Członkowski A., Członkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol 1999, 156:50-61.
195. Langston J.W., Ballard P., Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
196. Langston J.W., Forno L.S., Rebert C.S., Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 1984, 292:390-394.
197. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999, 46:598-605.
198. Langston J.W., Irwin I. MPTP: current concepts and controversies. Clin Neuropharmacol 1986, 9:485-507.
199. Lapointe N., St-Hilaire M., Martinoli M.G., Blanchet J., Gould P., Rouillard C., Cicchetti F. Rotenone induces non-specific central nervous system and systemic toxicity. FASEB J 2004, 18:717-719.
200. Lee C.S., Sauer H., Björklund A. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat. Neuroscience 1996, 72:641-653.
201. Lemay S., Chouinard S., Blanchet P., Masson H., Soland V., Beuter A., Bédard M.A. Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:31-39.
202. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., Dawson V.L., Dawson T.M., Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999, 5:1403-1409.
203. Limousin P., Krack P., Pollak P., Benazzouz A., Ardouin C., Hoffmann D., Benabid A.L. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998, 339:1105-1111.
204. Liou H.H., Tsai M.C., Chen C.J., Jeng J.S., Chang Y.C., Chen S.Y., Chen R.C. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology 1997, 48:1583-1588.
205. Liu Y., Roghani A., Edwards R.H. Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium. Proc Natl Acad Sci U S A 1992, 89:9074-9078.
206. LoPachin R.M., Gavin T. Response to "paraquat: the red herring of Parkinson's disease research". Toxicol Sci 2008, 103:219-221.
207. Lotharius J., O'Malley K.L. The Parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J Biol Chem 2000, 275:38581-38588.
208. Luthman J., Fredriksson A., Sundström E., Jonsson G., Archer T. Selective lesion of central dopamine or noradrenaline neuron systems in the neonatal rat: motor behavior and monoamine alterations at adult stage. Behav Brain Res 1989, 33:267-277.
209. Maggio R., Riva M., Vaglini F., Fornai F., Molteni R., Armogida M., Racagni G., Corsini G.U. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J Neurochem 1998, 71:2439-2446.
210. Manning-Bog A.B., McCormack A.L., Li J., Uversky V.N., Fink A.L., Di Monte D.A. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem 2002, 277:1641-1644.
211. Manning-Bog A.B., McCormack A.L., Purisai M.G., Bolin L.M., Di Monte D.A. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci 2003, 23:3095-3099.
212. Marinova-Mutafchieva L., Sadeghian M., Broom L., Davis J.B., Medhurst A.D., Dexter D.T. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease. J Neurochem 2009, 110:966-975.
213. Markey S.P., Johannessen J.N., Chiueh C.C., Burns R.S., Herkenham M.A. Intraneuronal generation of a pyridinium metabolite may cause drug-induced Parkinsonism. Nature 1984, 311:464-467.
214. Marshall L.E., Himes R.H. Rotenone inhibition of tubulin self-assembly. Biochim Biophys Acta 1978, 543:590-594.
215. Marti M.J., James C.J., Oo T.F., Kelly W.J., Burke R.E. Early developmental destruction of terminals in the striatal target induces apoptosis in dopamine neurons of the substantia nigra. J Neurosci 1997, 17:2030-2039.
216. Marti M.J., Saura J., Burke R.E., Jackson-Lewis V., Jiménez A., Bonastre M., Tolosa E. Striatal 6-hydroxydopamine induces apoptosis of nigral neurons in the adult rat. Brain Res 2002, 958:185-191.
217. Mayorga A.J., Lucki I. Limitations on the use of the C57BL/6 mouse in the tail suspension test. Psychopharmacol Berl 2001, 155:110-112.
218. McCormack A.L., Atienza J.G., Johnston L.C., Andersen J.K., Vu S., Di Monte D.A. Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. J Neurochem 2005, 93:1030-1037.
219. McCormack A.L., Di Monte D.A. Effects of L-dopa and other amino acids against paraquat-induced nigrostriatal degeneration. J Neurochem 2003, 85:82-86.
220. McCormack A.L., Thiruchelvam M., Manning-Bog A.B., Thiffault C., Langston J.W., Cory-Slechta D.A., Di Monte D.A. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 2002, 10:119-127.
221. McGeer P.L., Schwab C., Parent A., Doudet D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol 2003, 54:599-604.
222. Meissner W., Prunier C., Guilloteau D., Chalon S., Gross C.E., Bezard E. Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. Mol Neurobiol 2003, 28:209-218.
223. Mera T.O., Johnson M.D., Rothe D., Zhang J., Xu W., Ghosh D., Vitek J., Alberts J.L. Objective quantification of arm rigidity in MPTP-treated primates. J Neurosci Methods 2009, 177:20-29.
224. Miller G.W. Paraquat: the red herring of Parkinson's disease research. Toxicol Sci 2007, 100:1-2.
225. Mitchell I.J., Cross A.J., Sambrook M.A., Crossman A.R. Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus. Neurosci Lett 1985, 61:195-200.
226. Mladenović A., Perović M., Raicević N., Kanazir S., Rakić L., Ruzdijić S. 6-hydroxydopamine increases the level of TNFalpha and bax mRNA in the striatum and induces apoptosis of dopaminergic neurons in hemiparkinsonian rats. Brain Res 2004, 996:237-245.
227. Montoya C.P., Astell S., Dunnett S.B. Effects of nigral and striatal grafts on skilled forelimb use in the rat. Prog Brain Res 1990, 82:459-466.
228. Montoya C.P., Campbell-Hope L.J., Pemberton K.D., Dunnett S.B. The "staircase test": a measure of independent forelimb reaching and grasping abilities in rats. J Neurosci Methods 1991, 36:219-228.
229. Moratalla R., Quinn B., DeLanney L.E., Irwin I., Langston J.W., Graybiel A.M. Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A 1992, 89:3859-3863.
230. Mori A., Ohashi S., Nakai M., Moriizumi T., Mitsumoto Y. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice. Neurosci Res 2005, 51:265-274.
231. Mounayar S., Boulet S., Tandé D., Jan C., Pessiglione M., Hirsch E.C., Féger J., Savasta M., François C., Tremblay L. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery. Brain 2007, 130:2898-2914.
232. Muñoz A., Li Q., Gardoni F., Marcello E., Qin C., Carlsson T., Kirik D., Di Luca M., Björklund A., Bezard E., Carta M. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008, 131:3380-3394.
233. Muthane U., Ramsay K.A., Jiang H., Jackson-Lewis V., Donaldson D., Fernando S., Ferreira M., Przedborski S. Differences in nigral neuron number and sensitivity to 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1mice. Exp Neurol 1994, 126:195-204.
234. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 1985, 36:2503-2508.
235. Oiwa Y., Sanchez-Pernaute R., Harvey-White J., Bankiewicz K.S. Progressive and extensive dopaminergic degeneration induced by convection-enhanced delivery of 6-hydroxydopamine into the rat striatum: a novel rodent model of Parkinson disease. J Neurosurg 2003, 98:136-144.
236. Olsson M., Nikkhah G., Bentlage C., Björklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 1995, 15:3863-3875.
237. Ovadia A., Zhang Z., Gash D.M. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol Aging 1995, 16:931-937.
238. Pabon M.M., Bachstetter A.D., Hudson C.E., Gemma C., Bickford P.C. CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease. J Neuroinflammation 2011, 8:9.
239. Pan-Montojo F., Anichtchik O., Dening Y., Knels L., Pursche S., Jung R., Jackson S., Gille G., Spillantini M.G., Reichmann H., Funk R.H. Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS ONE 2010, 5:e8762.
240. Papa S.M., Engber T.M., Kask A.M., Chase T.N. Motor fluctuations in L-dopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 1994, 662:69-74.
241. Parain K., Hapdey C., Rousselet E., Marchand V., Dumery B., Hirsch E.C. Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine parkinsonian toxin. Brain Res 2003, 984:224-232.
242. Parker W.D., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989, 26:719-723.
243. Peng J., Mao X.O., Stevenson F.F., Hsu M., Andersen J.K. The herbicide paraquat induces dopaminergic nigral apoptosis through sustained activation of the JNK pathway. J Biol Chem 2004, 279:32626-32632.
244. Peng J., Oo M.L., Andersen J.K. Synergistic effects of environmental risk factors and gene mutations in Parkinson's disease accelerate age-related neurodegeneration. J Neurochem 2010, 115:1363-1373.
245. Peng J., Peng L., Stevenson F.F., Doctrow S.R., Andersen J.K. Iron and paraquat as synergistic environmental risk factors in sporadic Parkinson's disease accelerate age-related neurodegeneration. J Neurosci 2007, 27:6914-6922.
246. Peng J., Stevenson F.F., Doctrow S.R., Andersen J.K. Superoxide dismutase/catalase mimetics are neuroprotective against selective paraquat-mediated dopaminergic neuron death in the substantial nigra: implications for Parkinson disease. J Biol Chem 2005, 280:29194-29198.
247. Peng J., Stevenson F.F., Oo M.L., Andersen J.K. Iron-enhanced paraquat-mediated dopaminergic cell death due to increased oxidative stress as a consequence of microglial activation. Free Radic Biol Med 2009, 46:312-320.
248. Pérez-Otaño I., Herrero M.T., Oset C., De Ceballos M.L., Luquin M.R., Obeso J.A., Del Río J. Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset. Brain Res 1991, 567:127-132.
249. Perier C, Bove J, Vila M (in press) Mitochondria and programmed cell death in Parkinson's disease: apoptosis and beyond. Antioxid Redox Signal, in press.
250. Perier C., Bove J., Wu D.C., Dehay B., Choi D.K., Jackson-Lewis V., Rathke-Hartlieb S., Bouillet P., Strasser A., Schulz J.B., Przedborski S., Vila M. Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc Natl Acad Sci U S A 2007, 104:8161-8166.
251. Perier C., Tieu K., Guégan C., Caspersen C., Jackson-Lewis V., Carelli V., Martinuzzi A., Hirano M., Przedborski S., Vila M. Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci U S A 2005, 102:19126-19131.
252. Pessiglione M., Guehl D., Jan C., François C., Hirsch E.C., Féger J., Tremblay L. Disruption of self-organized actions in monkeys with progressive MPTP-induced Parkinsonism: part II. Effects of reward preference. Eur J Neurosci 2004, 19:437-446.
253. Peterson L.A., Caldera P.S., Trevor A., Chiba K., Castagnoli N. Studies on the 1-methyl-4-phenyl-2,3-dihydropyridinium species 2,3-MPDP+, the monoamine oxidase catalyzed oxidation product of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Med Chem 1985, 28:1432-1436.
254. Petroske E., Meredith G.E., Callen S., Totterdell S., Lau Y.S. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 2001, 106:589-601.
255. Pierri M., Vaudano E., Sager T., Englund U. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 2005, 48:517-524.
256. Pinna A. Novel investigational adenosine A2A receptor antagonists for Parkinson's disease. Expert Opin Investig Drugs 2009, 18:1619-1631.
257. Pinna A., Pontis S., Borsini F., Morelli M. Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease. Synapse 2007, 61:606-614.
258. Porter C.C., Totaro J.A., Stone C.A. Effect of 6-hydroxydopamine and some other compounds on the concentration of norepinephrine in the hearts of mice. J Pharmacol Exp Ther 1963, 140:308-316.
259. Prasad K., Tarasewicz E., Mathew J., Strickland P.A., Buckley B., Richardson J.R., Richfield E.K. Toxicokinetics and toxicodynamics of paraquat accumulation in mouse brain. Exp Neurol 2009, 215:358-367.
260. Prediger R.D., Batista L.C., Medeiros R., Pandolfo P., Florio J.C., Takahashi R.N. The risk is in the air: intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Exp Neurol 2006, 202:391-403.
261. Prediger R.D., Rial D., Medeiros R., Figueiredo C.P., Doty R.L., Takahashi R.N. Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease. Ann N Y Acad Sci 2009, 1170:629-636.
262. Przedborski S., Ischiropoulos H. Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease. Antioxid Redox Signal 2005, 7:685-693.
263. Przedborski S., Jackson-Lewis V., Kostic V., Carlson E., Epstein C.J., Cadet J.L. Superoxide dismutase, catalase, and glutathione peroxidase activities in copper/zinc-superoxide dismutase transgenic mice. J Neurochem 1992, 58:1760-1767.
264. Przedborski S., Jackson-Lewis V., Naini A.B., Jakowec M., Petzinger G., Miller R., Akram M. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 2001, 76:1265-1274.
265. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., Togasaki D.M. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 1995, 67:631-647.
266. Przedborski S., Vila M. MPTP: a review of its mechanisms of neurotoxicity. Clin Neurosci Res 2001, 1:407-418.
267. Przedborski S., Vila M. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 2003, 991:189-198.
268. Purisai M.G., McCormack A.L., Cumine S., Li J., Isla M.Z., Di Monte D.A. Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol Dis 2007, 25:392-400.
269. Quik M., Parameswaran N., McCallum S.E., Bordia T., Bao S., McCormack A., Kim A., Tyndale R.F., Langston J.W., Di Monte D.A. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J Neurochem 2006, 98:1866-1875.
270. Rascol O., Poewe W., Lees A., Aristin M., Salin L., Juhel N., Waldhauser L., Schindler T. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS study. Arch Neurol 2008, 65:577-583.
271. Riachi N.J., LaManna J.C., Harik S.I. Entry of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine into the rat brain. J Pharmacol Exp Ther 1989, 249:744-748.
272. Richter F., Hamann M., Richter A. Chronic rotenone treatment induces behavioral effects but no pathological signs of parkinsonism in mice. J Neurosci Res 2007, 85:681-691.
273. Ries V., Henchcliffe C., Kareva T., Rzhetskaya M., Bland R., During M.J., Kholodilov N., Burke R.E. Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proc Natl Acad Sci U S A 2006, 103:18757-18762.
274. Ries V., Silva R.M., Oo T.F., Cheng H.C., Rzhetskaya M., Kholodilov N., Flavell R.A., Kuan C.Y., Rakic P., Burke R.E. JNK2 and JNK3 combined are essential for apoptosis in dopamine neurons of the substantia nigra, but are not required for axon degeneration. J Neurochem 2008, 107:1578-1588.
275. Ritz B., Ascherio A., Checkoway H., Marder K.S., Nelson L.M., Rocca W.A., Ross G.W., Strickland D., Van Den Eeden S.K., Gorell J. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 2007, 64:990-997.
276. Rojo A.I., Montero C., Salazar M., Close R.M., Fernández-Ruiz J., Sánchez-González M.A., de Sagarra M.R., Jackson-Lewis V., Cavada C., Cuadrado A. Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice. Eur J Neurosci 2006, 24:1874-1884.
277. Rolland A.S., Tandé D., Herrero M.T., Luquin M.R., Vazquez-Claverie M., Karachi C., Hirsch E.C., François C. Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication. J Neurochem 2009, 110:1321-1329.
278. Ros-Bernal F., Hunot S., Herrero M.T., Parnadeau S., Corvol J.C., Lu L., Alvarez-Fischer D., Carrillo-de Sauvage M.A., Saurini F., Coussieu C., Kinugawa K., Prigent A., Höglinger G., Hamon M., Tronche F., Hirsch E.C., Vyas S. Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proc Natl Acad Sci U S A 2011, 108:6632-6637.
279. Rose S., Jackson M.J., Smith L.A., Stockwell K., Johnson L., Carminati P., Jenner P. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets. Eur J Pharmacol 2006, 546:82-87.
280. Rose S., Ramsay C.N., Jenner P. The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of L-dopa in unilaterally 6-OHDA-lesioned rats. Brain Res 2007, 1133:110-114.
281. Rossetti Z.L., Sotgiu A., Sharp D.E., Hadjiconstantinou M., Neff N.H. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro. Biochem Pharmacol 1988, 37:4573-4574.
282. Roy N.S., Cleren C., Singh S.K., Yang L., Beal M.F., Goldman S.A. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med 2006, 12:1259-1268.
283. Rozas G., López-Martín E., Guerra M.J., Labandeira-García J.L. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J Neurosci Methods 1998, 83:165-175.
284. Russ H., Mihatsch W., Gerlach M., Riederer P., Przuntek H. Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?. Neurosci Lett 1991, 123:115-118.
285. Russell W.M., Burch R.L. The principles of humane experimental technique 1959, Methuen, London.
286. Ryan R.E., Ross S.A., Drago J., Loiacono R.E. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice. Br J Pharmacol 2001, 132:1650-1656.
287. Rylander D., Iderberg H., Li Q., Dekundy A., Zhang J., Li H., Baishen R., Danysz W., Bezard E., Cenci M.A. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis 2010, 39:352-361.
288. Sanchez-Ramos J.R., Övervik E., Ames B.N. A marker of oxyradical-mediated DNA damage (8-Hydroxy-2deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 1994, 3:197-204.
289. Saner A., Thoenen H. Model experiments on the molecular mechanism of action of 6-hydroxydopamine. Mol Pharmacol 1971, 7:147-154.
290. Sarre S., Yuan H., Jonkers N., Van Hemelrijck A., Ebinger G., Michotte Y. In vivo characterization of somatodendritic dopamine release in the substantia nigra of 6-hydroxydopamine-lesioned rats. J Neurochem 2004, 90:29-39.
291. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994, 59:401-415.
292. Saura J., Parés M., Bové J., Pezzi S., Alberch J., Marin C., Tolosa E., Martí M.J. Intranigral infusion of interleukin-1beta activates astrocytes and protects from subsequent 6-hydroxydopamine neurotoxicity. J Neurochem 2003, 85:651-661.
293. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990, 54:823-827.
294. Schuler F., Casida J.E. Functional coupling of PSST and ND1 subunits in NADH: ubiquinone oxidoreductase established by photoaffinity labeling. Biochim Biophys Acta 2001, 1506:79-87.
295. Sedelis M., Schwarting R.K., Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 2001, 125:109-125.
296. Seitz G., Stegmann H.B., Jäger H.H., Schlude H.M., Wolburg H., Roginsky V.A., Niethammer D., Bruchelt G. Neuroblastoma cells expressing the noradrenaline transporter are destroyed more selectively by 6-fluorodopamine than by 6-hydroxydopamine. J Neurochem 2000, 75:511-520.
297. Seniuk N.A., Tatton W.G., Greenwood C.E. Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res 1990, 527:7-20.
298. Sherer T.B., Kim J.H., Betarbet R., Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 2003, 179:9-16.
299. Shimizu K., Ohtaki K., Matsubara K., Aoyama K., Uezono T., Saito O., Suno M., Ogawa K., Hayase N., Kimura K., Shiono H. Carrier-mediated processes in blood-brain barrier penetration and neural uptake of paraquat. Brain Res 2001, 906:135-142.
300. Simon D.K., Swearingen C.J., Hauser R.A., Trugman J.M., Aminoff M.J., Singer C., Truong D., Tilley B.C. Caffeine and progression of Parkinson disease. Clin Neuropharmacol 2008, 31:189-196.
301. Smeyne M., Jiao Y., Shepherd K.R., Smeyne R.J. Glia cell number modulates sensitivity to MPTP in mice. Glia 2005, 52:144-152.
302. Smith J.G. Paraquat poisoning by skin absorption: a review. Hum Toxicol 1988, 7:15-19.
303. Smith R.D., Zhang Z., Kurlan R., McDermott M., Gash D.M. Developing a stable bilateral model of parkinsonism in rhesus monkeys. Neuroscience 1993, 52:7-16.
304. Snow B.J., Vingerhoets F.J., Langston J.W., Tetrud J.W., Sossi V., Calne D.B. Pattern of dopaminergic loss in the striatum of humans with MPTP induced Parkinsonism. J Neurol Neurosurg, Psychiatry 2000, 68:313-316.
305. Sofic E., Lange K.W., Jellinger K., Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 1992, 142:128-130.
306. Soto-Otero R., Méndez-Alvarez E., Hermida-Ameijeiras A., Muñoz-Patiño A.M., Labandeira-Garcia J.L. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J Neurochem 2000, 74:1605-1612.
307. Spieles-Engemann A.L., Behbehani M.M., Collier T.J., Wohlgenant S.L., Steece-Collier K., Paumier K., Daley B.F., Gombash S., Madhavan L., Mandybur G.T., Lipton J.W., Terpstra B.T., Sortwell C.E. Stimulation of the rat subthalamic nucleus is neuroprotective following significant nigral dopamine neuron loss. Neurobiol Dis 2010, 39:105-115.
308. Sriram K., Matheson J.M., Benkovic S.A., Miller D.B., Luster M.I., O'Callaghan J.P. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J 2002, 16:1474-1476.
309. Staal R.G., Sonsalla P.K. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. J Pharmacol Exp Ther 2000, 293:336-342.
310. Swerdlow R.H., Parks J.K., Miller S.W., Tuttle J.B., Trimmer P.A., Sheehan J.P., Bennett J.P., Davis R.E., Parker W.D. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 1996, 40:663-671.
311. Takeuchi H., Yanagida T., Inden M., Takata K., Kitamura Y., Yamakawa K., Sawada H., Izumi Y., Yamamoto N., Kihara T., Uemura K., Inoue H., Taniguchi T., Akaike A., Takahashi R., Shimohama S. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models. J Neurosci Res 2009, 87:576-585.
312. Talpade D.J., Greene J.G., Higgins D.S., Greenamyre J.T. In vivo labeling of mitochondrial complex I (NADH: ubiquinone oxidoreductase) in rat brain using [(3)H]dihydrorotenone. J Neurochem 2000, 75:2611-2621.
313. Tanner C.M., Kamel F., Ross G.W., Hoppin J.A., Goldman S.M., Korell M., Marras C., Bhudhikanok G.S., Kasten M., Chade A.R., Comyns K., Richards M.B., Meng C., Priestley B., Fernandez H.H., Cambi F., Umbach D.M., Blair A., Sandler D.P., Langston J.W. Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect 2011, 119:866-872.
314. Tapias V., Cannon J.R., Greenamyre J.T. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model. J Neurosci Res 2010, 88:420-427.
315. Tatton N.A., Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 1997, 77:1037-1048.
316. Tayarani-Binazir K., Jackson M.J., Rose S., McCreary A.C., Jenner P. The partial dopamine agonist pardoprunox (SLV308) administered in combination with L-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets. Exp Neurol 2010, 226:320-327.
317. Taylor J.R., Elsworth J.D., Roth R.H., Sladek J.R., Redmond D.E. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus). Neuroscience 1997, 81:745-755.
318. Tetrud J.W., Langston J.W., Redmond D.E., Roth R.H., Sladek J.R., Angel R.W. MPTP-induced tremor in human and non-human primates. Neurology 1986, 36(Suppl 1):308.
319. Thacker E.L., O'Reilly E.J., Weisskopf M.G., Chen H., Schwarzschild M.A., McCullough M.L., Calle E.E., Thun M.J., Ascherio A. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology 2007, 68:764-768.
320. Thiffault C., Langston J.W., Di Monte D.A. Increased striatal dopamine turnover following acute administration of rotenone to mice. Brain Res 2000, 885:283-288.
321. Thiruchelvam M., Brockel B.J., Richfield E.K., Baggs R.B., Cory-Slechta D.A. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease?. Brain Res 2000, 873:225-234.
322. Thiruchelvam M., Richfield E.K., Baggs R.B., Tank A.W., Cory-Slechta D.A. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J Neurosci 2000, 20:9207-9214.
323. Tillerson J.L., Caudle W.M., Reverón M.E., Miller G.W. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Exp Neurol 2002, 178:80-90.
324. 3 receptor protein and mRNA in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) denervation in baboons. J Neurosci 1996, 16:7776-7782.
325. Tolosa E., Gaig C., Santamaría J., Compta Y. Diagnosis and the premotor phase of Parkinson disease. Neurology 2009, 72:S12-S20.
326. Tretiakoff C. Contribution a l'etude de l'anatomie pathologique du locus Niger de Soemmering avec quelques deductions relatives a la pathogenie des troubles du tonus musculaire et de la maladie de Parkinson 1919, Medical thesis, Paris.
327. Tronci E., Simola N., Borsini F., Schintu N., Frau L., Carminati P., Morelli M. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. Eur J Pharmacol 2007, 566:94-102.
328. Ungerstedt U. 6-hydroxydopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 1968, 5:107-110.
329. Ungerstedt U. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 1971, 367:95-122.
330. Ungerstedt U. Postsynaptique supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal system in the rat brain. Acta Physiol Scand Suppl 1971, 367:69-93.
331. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res 1970, 24:485-493.
332. Vandeputte C., Taymans J.M., Casteels C., Coun F., Ni Y., Van Laere K., Baekelandt V. Automated quantitative gait analysis in animal models of movement disorders. BMC Neurosci 2010, 11:92.
333. Verhave P.S., Vanwersch R.A., van Helden H.P., Smit A.B., Philippens I.H. Two new test methods to quantify motor deficits in a marmoset model for Parkinson's disease. Behav Brain Res 2009, 200:214-219.
334. Vieregge A., Sieberer M., Jacobs H., Hagenah J.M., Vieregge P. Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study. Neurology 2001, 57:1032-1035.
335. Vila M., Bové J., Dehay B., Rodríguez-Muela N., Boya P. Lysosomal membrane permeabilization in Parkinson disease. Autophagy 2011, 7:98-100.
336. Vila M., Jackson-Lewis V., Vukosavic S., Djaldetti R., Liberatore G., Offen D., Korsmeyer S.J., Przedborski S. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 2001, 98:2837-2842.
337. Vila M., Przedborski S. Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 2003, 4:365-375.
338. Vila M., Ramonet D., Perier C. Mitochondrial alterations in Parkinson's disease: new clues. J Neurochem 2008, 107:317-328.
339. Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowec M., Przedborski S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem 2000, 74:721-729.
340. Villafane G., Cesaro P., Rialland A., Baloul S., Azimi S., Bourdet C., Le Houezec J., Macquin-Mavier I., Maison P. Chronic high dose transdermal nicotine in Parkinson's disease: an open trial. Eur J Neurol 2007, 14:1313-1316.
341. Villalba R.M., Lee H., Smith Y. Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys. Exp Neurol 2009, 215:220-227.
342. Vingerhoets F.J., Snow B.J., Tetrud J.W., Langston J.W., Schulzer M., Calne D.B. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol 1994, 36:765-770.
343. Visanji N.P., O'Neill M.J., Duty S. Nicotine, but neither the alpha4beta2 ligand RJR2403 nor an alpha7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle. Neuropharmacology 2006, 51:506-516.
344. Wahlsten D., Metten P., Phillips T.J., Boehm S.L., Burkhart-Kasch S., Dorow J., Doerksen S., Downing C., Fogarty J., Rodd-Henricks K., Hen R., McKinnon C.S., Merrill C.M., Nolte C., Schalomon M., Schlumbohm J.P., Sibert J.R., Wenger C.D., Dudek B.C., Crabbe J.C. Different data from different labs: lessons from studies of gene-environment interaction. J Neurobiol 2003, 54:283-311.
345. Wang A., Costello S., Cockburn M., Zhang X., Bronstein J., Ritz B. Parkinson's disease risk from ambient exposure to pesticides. Eur J Epidemiol 2011, 26:547-555.
346. Willis G.L., Donnan G.A. Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice. Brain Res 1987, 402:269-274.
347. Winkler C., Kirik D., Björklund A., Cenci M.A. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 2002, 10:165-186.
348. Wu X.F., Block M.L., Zhang W., Qin L., Wilson B., Zhang W.Q., Veronesi B., Hong J.S. The role of microglia in paraquat-induced dopaminergic neurotoxicity. Antioxid Redox Signal 2005, 7:654-661.
349. Xu K., Xu Y.H., Chen J.F., Schwarzschild M.A. Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease. Neuroscience 2010, 167:475-481.
350. Zaidel A., Spivak A., Grieb B., Bergman H., Israel Z. Subthalamic span of beta oscillations predicts deep brain stimulation efficacy for patients with Parkinson's disease. Brain 2010, 133:2007-2021.
351. Zhu C., Vourc'h P., Fernagut P.O., Fleming S.M., Lacan S., Dicarlo C.D., Seaman R.L., Chesselet M.F. Variable effects of chronic subcutaneous administration of rotenone on striatal histology. J Comp Neurol 2004, 478:418-426.